{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:25:22Z","timestamp":1780385122565,"version":"3.54.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>One potential medication for treating methamphetamine use disorder is the opioid antagonist naltrexone (NLTX). Despite encouraging preclinical findings, the results of clinical studies have been mixed. The primary aim of the current trial was to examine the effects of acute NLTX pretreatment on the subjective and reinforcing effects of intranasal methamphetamine. Nonmedical psychostimulant users completed outpatient testing sessions in which they received oral placebo (0\u2009mg) or NLTX (50\u2009mg) before intranasal methamphetamine (30\u2009mg\/70\u2009kg). Primary outcome measures were peak positive subjective effects (e.g. drug \u2018Liking\u2019) assessed on a visual analog scale (0\u2013100), and methamphetamine self-administration using an operant self-administration task. Participants also completed a probabilistic categorization task to assess reward and punishment learning sensitivity. Complete data were available from 13 male and 1 transgender (male-to-female) participant (age: 33.4\u2009\u00b1\u20097.6\u2009years). Intranasal methamphetamine significantly increased subjective ratings of drug \u2018Liking\u2019, \u2018Good Effect\u2019 and \u2018High\u2019 from baseline (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2019s\u2009&lt;\u20090.01), but did not significantly vary as a function of placebo or NLTX pretreatment. Similarly, methamphetamine self-administration did not vary between the placebo and NLTX pretreatment conditions. This sample did not demonstrate a significant \u2018bias\u2019 in learning from positive and negative outcomes (i.e. reward and punishment sensitivity), and reward\/punishment sensitivity was not correlated with the effects of methamphetamine or the effects of NLTX on methamphetamine. The current study argues against the use of NLTX as a stand-alone medication for treating methamphetamine use disorder.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000671","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T15:23:05Z","timestamp":1650381785000},"page":"255-265","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward\/punishment sensitivity and methamphetamine\u2019s effects"],"prefix":"10.1097","volume":"33","author":[{"given":"Jermaine D.","family":"Jones","sequence":"first","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudassir","family":"Mumtaz","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Molecular Medicine, The City University of New York School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal P.","family":"Vadhan","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra\/Northwell Feinstein Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suky","family":"Martinez","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satadru","family":"Pramanik","sequence":"additional","affiliation":[{"name":"Mailman School of Public Health, Columbia University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Manubay","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Mogali","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freymon","family":"Perez","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Castillo","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry R.","family":"Kranzler","sequence":"additional","affiliation":[{"name":"Center for Studies of Addiction, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.drugalcdep.2017.08.003","article-title":"Glial and neuroinflammatory targets for treating substance use disorders.","volume":"180","author":"Bachtell","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ajad.12711","article-title":"Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies.","volume":"27","author":"Bisaga","year":"2018","journal-title":"Am J Addict"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/brain\/awp094","article-title":"Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson\u2019s patients.","volume":"132","author":"B\u00f3di","year":"2009","journal-title":"Brain"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archpsyc.1977.01770220063007","article-title":"Naltrexone and cyclazocine. A controlled treatment study.","volume":"34","author":"Brahen","year":"1977","journal-title":"Arch Gen Psychiatry"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","article-title":"Association of \u00b5-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.","volume":"17","author":"Chamorro","year":"2012","journal-title":"Addict Biol"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/add.13950","article-title":"Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.","volume":"113","author":"Coffin","year":"2018","journal-title":"Addiction"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FBP.0b013e32833bb9f8","article-title":"Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the behavioral pharmacology society.","volume":"21","author":"Comer","year":"2010","journal-title":"Behav Pharmacol"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.pain.2012.07.035","article-title":"Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.","volume":"153","author":"Comer","year":"2012","journal-title":"Pain"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/npp.2013.143","article-title":"Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers.","volume":"38","author":"Comer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1360-0443.1991.tb01749.x","article-title":"Utility of subjective-effects measurements in assessing abuse liability of drugs in humans.","volume":"86","author":"Fischman","year":"1991","journal-title":"Br J Addict"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.euroneuro.2010.06.018","article-title":"A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence.","volume":"20","author":"Grant","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbr.2008.08.021","article-title":"The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat.","volume":"197","author":"H\u00e4ggkvist","year":"2009","journal-title":"Behav Brain Res"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1369-1600.2009.00150.x","article-title":"The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat.","volume":"14","author":"H\u00e4ggkvist","year":"2009","journal-title":"Addict Biol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.npp.1301578","article-title":"Acute physiological and behavioral effects of intranasal methamphetamine in humans.","volume":"33","author":"Hart","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/add.14975","article-title":"Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.","volume":"115","author":"Hartwell","year":"2020","journal-title":"Addiction"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/02791072.1988.10472494","article-title":"Pharmacological adjuncts in the treatment of opioid and cocaine addicts.","volume":"20","author":"Herridge","year":"1988","journal-title":"J Psychoactive Drugs"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.jcp.0000144893.29987.e5","article-title":"Effects of naltrexone on the subjective response to amphetamine in healthy volunteers.","volume":"24","author":"Jayaram-Lindstr\u00f6m","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/sj.npp.1301572","article-title":"Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence.","volume":"33","author":"Jayaram-Lindstr\u00f6m","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1176\/appi.ajp.2008.08020304","article-title":"Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.","volume":"165","author":"Jayaram-Lindstr\u00f6m","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FBP.0b013e3283423d55","article-title":"Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys.","volume":"22","author":"Jimenez-Gomez","year":"2011","journal-title":"Behav Pharmacol"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/FBP.0b013e3283641c3d","article-title":"A review of human drug self-administration procedures.","volume":"24","author":"Jones","year":"2013","journal-title":"Behav Pharmacol"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.03.003","article-title":"A review of pharmacogenetic studies of drug use disorders.","volume":"152","author":"Jones","year":"2015","journal-title":"Drug Alc Depend"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/acer.12643","article-title":"The pharmacogenetics of alcohol use disorder.","volume":"39","author":"Jones","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40263-020-00721-9","article-title":"Potential of glial cell modulators in the management of substance use disorders.","volume":"34","author":"Jones","year":"2020","journal-title":"CNS Drugs"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1360-0443.2011.03706.x","article-title":"Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans.","volume":"107","author":"Kirkpatrick","year":"2012","journal-title":"Addiction"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fpsyt.2019.00603","article-title":"Effects of naltrexone on large-scale network interactions in methamphetamine use disorder.","volume":"10","author":"Kohno","year":"2019","journal-title":"Front Psychiatry"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis.","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"R38-20250614","first-page":"1207","article-title":"Duration of occupancy of opiate receptors by naltrexone.","volume":"29","author":"Lee","year":"1988","journal-title":"J Nucl Med"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00213-019-05330-z","article-title":"Impairments in reinforcement learning do not explain enhanced habit formation in cocaine use disorder.","volume":"236","author":"Lim","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00213-014-3449-x","article-title":"Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.","volume":"231","author":"Marks","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/JCP.0000000000000488","article-title":"Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.","volume":"36","author":"Marks","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.addbeh.2006.05.022","article-title":"Motives, diversion and routes of administration associated with nonmedical use of prescription opioids.","volume":"32","author":"McCabe","year":"2007","journal-title":"Addict Behav"},{"key":"R43-20250614","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0740-5472(98)00039-7","article-title":"The effects of naltrexone on alcohol and cocaine use in dually addicted patients.","volume":"16","author":"Oslin","year":"1999","journal-title":"J Subst Abuse Treat"},{"key":"R44-20250614","doi-asserted-by":"crossref","first-page":"7814","DOI":"10.1523\/JNEUROSCI.4063-13.2014","article-title":"Impulse control disorders in Parkinson\u2019s disease are associated with dysfunction in stimulus valuation but not action valuation.","volume":"34","author":"Piray","year":"2014","journal-title":"J Neurosci"},{"key":"R45-20250614","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.2146\/ajhp160542","article-title":"Topiramate in the treatment of cocaine use disorder.","volume":"75","author":"Prince","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"R46-20250614","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/npp.2015.83","article-title":"The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study.","volume":"40","author":"Ray","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"R48-20250614","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/WNF.0b013e318261e193","article-title":"Co-occurring psychotic and addictive disorders: neurobiology and diagnosis.","volume":"35","author":"Ross","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"R49-20250614","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/ADM.0000000000000297","article-title":"Extended-Release injectable naltrexone (XR-NTX) with intensive psychosocial therapy for amphetamine-dependent persons seeking treatment: a placebo-controlled trial.","volume":"11","author":"R\u00fanarsd\u00f3ttir","year":"2017","journal-title":"J Addict Med"},{"key":"R50-20250614","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MOP.0b013e3283504fbf","article-title":"Psychiatric disease and drug abuse.","volume":"24","author":"Santucci","year":"2012","journal-title":"Curr Opin Pediatr"},{"key":"R51-20250614","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(94)00726-N","article-title":"Naloxone reduces the neurochemical and behavioral effects of amphetamine but not those of cocaine.","volume":"275","author":"Schad","year":"1995","journal-title":"Eur J Pharm"},{"key":"R52-20250614","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1601-183X.2011.00700.x","article-title":"Sensitivity to rewarding or aversive effects of methamphetamine determines methamphetamine intake.","volume":"10","author":"Shabani","year":"2011","journal-title":"Genes Brain Behav"},{"key":"R53-20250614","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1037\/0893-164X.22.3.444","article-title":"Methamphetamine use in a rural college population: associations with marijuana use, sensitivity to punishment, and sensitivity to reward.","volume":"22","author":"Simons","year":"2008","journal-title":"Psychol Addict Behav"},{"key":"R54-20250614","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"R55-20250614","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pbb.2014.11.018","article-title":"Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.","volume":"129","author":"Stoops","year":"2015","journal-title":"Pharmacol Biochem Behav"},{"key":"R56-20250614","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.drugalcdep.2016.06.022","article-title":"Differential sensitivity to learning from positive and negative outcomes in cocaine users.","volume":"166","author":"Strickland","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"R57-20250614","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial.","volume":"169","author":"Tiihonen","year":"2012","journal-title":"Am J Psychiatry"},{"key":"R58-20250614","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1369-1600.2009.00161.x","article-title":"Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats.","volume":"14","author":"Todtenkopf","year":"2009","journal-title":"Addict Biol"},{"key":"R59-20250614","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa2020214","article-title":"Bupropion and naltrexone in methamphetamine use disorder.","volume":"384","author":"Trivedi","year":"2021","journal-title":"N Engl J Med"},{"key":"R60-20250614","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.mcna.2016.03.011","article-title":"Pharmacotherapy for substance use disorders.","volume":"100","author":"Wilson-Klein","year":"2016","journal-title":"Med Clin North Am"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:02:47Z","timestamp":1749938567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000671","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}